:::
字體字級:較小字體預設字體較大字體
  • 圖檔連結:門診表(開新視窗)
  • 圖檔連結:網路掛號(開新視窗)
  • 圖檔連結:交通資訊(開新視窗)
  • 圖檔連結:病人安全(開新視窗)
  • 圖檔連結:就醫須知(開新視窗)
  • 圖檔連結:社服及捐助(開新視窗)
  • 圖檔連結:高齡友善(開新視窗)
  • 圖檔連結:新北精神醫療網(開新視窗)
  • 圖檔連結:IRB專區(開新視窗)
  • 圖檔政府公開資訊LOGO(開新視窗)
  • 圖檔連結:幸福手作(開新視窗)
  • 圖檔訂閱電子報(開新視窗)
  • 圖檔粉絲團(開新視窗)
  • 圖檔全文檢索連結(開新視窗)
  • 圖檔八里療養院粉絲團(開新視窗)
  • 圖檔中和社區復健中心-希望會館粉絲團(開新視窗)
  • 圖檔元氣身心健康中心粉絲團(開新視窗)
  • 圖檔日昇身心健康中心粉絲團(開新視窗)
  • 圖檔八里快樂村康家粉絲團(開新視窗)
  • 圖檔我愛日間大家庭粉絲團(開新視窗)
  • 圖檔連結Intranet(開新視窗)
  • 圖檔連結Webmail(開新視窗)
  • 圖檔連結院內子系統(開新視窗)
累計人數:
01979488
連結:本網站己通過無障礙A+(另開新視窗)
:::
捷徑位置 : 
 > 
 > 
臨床試驗中心
成立背景及目標 | 工作項目及團體成員 | 設施環境 | 歷年執行績效 | 院際合作臨床試驗網 | 課程與法規
■96-104年執行藥物試驗案情形

本院病患主要以重大精神疾病諸如思覺失調症及情感性精神病等,自臨床試驗團隊及病房成立後,由於各項軟硬體設備之整合,執行藥物試驗案效率較以往提升,也有助吸引藥廠至本院進行臨床研究。除原有重大精神疾病之藥物試驗案外,本院98年度開始於門診執行困難度較高之海洛因成癮個案之藥物試驗案,亦超前原訂收案目標。

■96-104年藥廠委託藥物試驗案清單
◎ 2012-2015 Global drug trial, phase II : MTPC MP214 study, sponsored by Mitsubishi-Tanabe Inc.
◎ 2012-2014 Global drug trial, phase Ⅳ: A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects with Schizophrenia, sponsored by Johnson & Johnson Inc.
◎ 2012-2014 Global drug trial, phase III : R092670PSY3011 A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia, sponsored by Johnson & Johnson Inc.
◎ 2012-2013 Global drug trial, Phase III, Multicenter, Randomized Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia Ⅲ Otsuka Pharmaceutical Co., Ltd
◎ 2010-2011 Global drug trial, phase III:A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Paliperidone Palmitate in Subjects With Schizophrenia, sponsored by Johnson & Johnson Inc
◎ 2010-2011 Global drug trial, phase III:A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia, sponsored by MSD Inc
◎ 2009-2010 Global drug trial, phase II:OTSUKA_331-07-203/331-08-210, sponsored by Otsuka Pharmaceutical Co., Ltd
◎ 2009 Global drug trial, phase III:A Multicenter,Randomized, Double-blind,Placebo-controlled,Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients with Bipolar Disorder Experiencing a Manic or Mixed Episode sponsored by Otsuka Pharmaceutical Co., Ltd
◎ 2009 Global drug trial, phase III:A plan of a Randomized, Double-blind, Placebo-controlled, Parallel-group Confirmatory Study of SM-13496 in Patients with Schizophrenia. , sponsored by Dainippon Sumitomo Pharma
◎ 2009 An Open Multi-Center Trial of Suboxone Treatment among Opiate Dependent Subjects, sponsored by Reckitt Benckiser Healthcare (UK) Ltd.
◎ 2007-2008 Global drug trial, phase III: R076477-SCH-4012, sponsored by Johnson & Johnson Pharmaceuticals.
◎ 2007 Global drug trial, phase III: A randomized, double blind, placebo and active-controlled parallel-group study to evaluate the efficacy and safety of risperidone and long-acting injectable for the prevention of mood episodes in the treatment of subjects with bipolar I disorder , sponsored by Johnson & Johnson Pharmaceuticals.
◎ 2007-2008 Quetiapine related neurochemical changes as measured by magnetic resonance spectroscopy in patients with schizophrenia, sponsored by National science Council
◎ 2007-2009 A Multi-Centre Comparative Study to Evaluate the Anti-aggression Effect and Safety of Zotepine versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward, sponsored by Astellas Pharmaceuticals.
圖檔:歷年藥物試驗執行狀況(開新視窗)
  • 歷年藥物試驗執行狀況
  • 非藥物試驗研究案
    2011年起分別與中央研究院、台大醫院精神部暨美國國家精神健康研究院(NIMH)、台北榮民總醫院跨院合作試驗案如下:

    ●難治型精神分裂症之基因體關聯性研究計畫(中央研究院合作案)
    ●睡眠研究 佐沛眠引發之類夢遊行為的藥物基因體學究計畫 (中央研究院合作案)
    ●臺灣精神分裂症全基因體相關研究(台大醫院精神部合作案)
    ●比較escitalopram 和duloxetine附加治療帶有第一型神經調節素基因(NRG1)危險基因型的精神分裂症患者的負性症狀的雙盲隨機安慰劑臨床試驗(台大醫院精神部合作案)

    無障礙宣告 | 隱私權政策 | 網站安全政策 | 資訊安全政策

    衛生福利部八里療養院

    電話:總機 02-26101660 醫療及轉介諮詢、顧客意見 02-26105915 
    傳真:02-26105916 處方疑義聯繫(02)26101660分機2504
    電子郵件:bali@balipc.gov.tw 
    新北市(24936)八里區華富山33號

    土城門診部-日昇身心健康中心

    [23656]新北市土城區青雲路6號
    掛號電話:02-2274-5250

    蘆洲門診部-元氣身心健康中心

    [24759]新北市蘆洲區光榮路116號
    掛號電話:02-8285-6224
    =============================================
    上次網站檢查日:107/03/22
    =============================================

    本網站內容所有權歸 衛生福利部八里療養院 所有,禁止任意轉載、複製或做商業用途。


    但以網路搜尋或超連結方式,進入醫療機構之網址(域)直接點閱者,不在此限。
    本網站建議使用IE7.0以上瀏覽器,最佳解析度為1024×768。
    網站問題請洽02-26101660(分機)1011